Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials (Q33315300)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

11 references

13 March 2019

23 March 2019

17 June 2019

30 June 2019

1 August 2019

20 November 2019

27 November 2019

26 September 2020

14 November 2020

1 February 2021

28 October 2022

0 references

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

0 references

0 references

rheumatoid arthritis

9 references

13 March 2019

23 March 2019

17 June 2019

30 June 2019

1 August 2019

20 November 2019

27 November 2019

26 September 2020

14 November 2020

bacterial infectious disease

9 references

13 March 2019

23 March 2019

17 June 2019

30 June 2019

1 August 2019

20 November 2019

27 November 2019

26 September 2020

14 November 2020

tumor necrosis factor

2 references

1 August 2019

1 February 2021

1 reference

20 November 2019

1 reference

27 November 2019

disease-modifying antirheumatic drug

1 reference

14 November 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C Salliot

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

M Dougados

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

L Gossec

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

language of work or name

0 references

publication date

18 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 January 2009

11 references

13 March 2019

23 March 2019

17 June 2019

30 June 2019

1 August 2019

20 November 2019

27 November 2019

26 September 2020

14 November 2020

1 February 2021

28 October 2022

Annals of the Rheumatic Diseases

12 references

Europe PubMed Central

PubMed publication ID

25 July 2017

13 March 2019

23 March 2019

17 June 2019

30 June 2019

1 August 2019

20 November 2019

27 November 2019

26 September 2020

14 November 2020

1 February 2021

28 October 2022

68

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

25-32

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

11 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

23 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

30 June 2019

Europe PubMed Central

1 August 2019

Europe PubMed Central

20 November 2019

Europe PubMed Central

27 November 2019

Europe PubMed Central

26 September 2020

Europe PubMed Central

14 November 2020

Europe PubMed Central

1 February 2021

Europe PubMed Central

28 October 2022

copyright status

0 references

on focus list of Wikimedia project

0 references

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Predictors of infection in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Bias in location and selection of studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

21 June 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2596305

31 October 2018

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.2007.083188

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33315300&oldid=1760345512"